Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Molecular mechanisms of bleeding disorderassociated GFI1BQ287* mutation and its affected pathways in megakaryocytes and platelets.

van Oorschot R, Hansen M, Koornneef JM, Marneth AE, Bergevoet SM, van Bergen MGJM, van Alphen FPJ, van der Zwaan C, Martens JHA, Vermeulen M, Jansen PWTC, Baltissen MPA, Gorkom BAPL, Janssen H, Jansen JH, von Lindern M, Meijer AB, van den Akker E, van der Reijden BA.

Haematologica. 2019 Jul;104(7):1460-1472. doi: 10.3324/haematol.2018.194555. Epub 2019 Jan 17.

2.

Inherited missense variants that affect GFI1B function do not necessarily cause bleeding diatheses.

van Oorschot R, Marneth AE, Bergevoet SM, van Bergen MGJM, Peerlinck K, Lentaigne CE, Millar CM, Westbury SK, Favier R, Erber WN, Turro E, Jansen JH, Ouwehand WH, McKinney HL; NIHR BioResource Collaborative Group, Downes K, Freson K, van der Reijden BA.

Haematologica. 2019 Jun;104(6):e260-e264. doi: 10.3324/haematol.2018.207712. Epub 2018 Dec 20. No abstract available.

3.

GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.

Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Vassen L, Lams RF, Bergevoet SM, Groothuis L, Mandoli A, Martens JHA, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Lo MC, Zhang DE, van der Reijden BA, Khandanpour C.

Haematologica. 2018 Sep;103(9):e395-e399. doi: 10.3324/haematol.2017.180844. Epub 2018 Apr 19. No abstract available.

4.

C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.

Marneth AE, Prange KHM, Al Hinai ASA, Bergevoet SM, Tesi N, Janssen-Megens EM, Kim B, Sharifi N, Yaspo ML, Kuster J, Sanders MA, Stoetman ECG, Knijnenburg J, Arentsen-Peters TCJM, Zwaan CM, Stunnenberg HG, van den Heuvel-Eibrink MM, Haferlach T, Fornerod M, Jansen JH, Valk PJM, van der Reijden BA, Martens JHA.

Leukemia. 2018 Mar;32(3):828-836. doi: 10.1038/leu.2017.280. Epub 2017 Sep 5.

PMID:
28871137
5.

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.

Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C.

Exp Hematol. 2016 Jul;44(7):590-595.e1. doi: 10.1016/j.exphem.2016.04.001. Epub 2016 Apr 11.

6.

A dominant-negative GFI1B mutation in the gray platelet syndrome.

Monteferrario D, Bolar NA, Marneth AE, Hebeda KM, Bergevoet SM, Veenstra H, Laros-van Gorkom BA, MacKenzie MA, Khandanpour C, Botezatu L, Fransen E, Van Camp G, Duijnhouwer AL, Salemink S, Willemsen B, Huls G, Preijers F, Van Heerde W, Jansen JH, Kempers MJ, Loeys BL, Van Laer L, Van der Reijden BA.

N Engl J Med. 2014 Jan 16;370(3):245-53. doi: 10.1056/NEJMoa1308130. Epub 2013 Dec 10. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

7.

Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer.

Noordermeer SM, Wennemers M, Bergevoet SM, van der Heijden A, Tönnissen E, Sweep FC, Jansen JH, Span PN, van der Reijden BA.

Breast Cancer Res Treat. 2012 Aug;135(1):125-33. doi: 10.1007/s10549-012-2122-5. Epub 2012 Jun 16.

8.

Human mitochondrial ATP-binding cassette transporter ABCB10 is required for efficient red blood cell development.

Tang L, Bergevoet SM, Bakker-Verweij G, Harteveld CL, Giordano PC, Nijtmans L, de Witte T, Jansen JH, Raymakers RA, van der Reijden BA.

Br J Haematol. 2012 Apr;157(1):151-4. doi: 10.1111/j.1365-2141.2011.08936.x. Epub 2011 Nov 16. No abstract available.

PMID:
22085049
9.

Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.

Tang L, Bergevoet SM, Gilissen C, de Witte T, Jansen JH, van der Reijden BA, Raymakers RA.

BMC Pharmacol. 2010 Sep 13;10:12. doi: 10.1186/1471-2210-10-12.

10.

Genetic polymorphisms in GSTA1, GSTP1, GSTT1, and GSTM1 and gastric cancer risk in a Vietnamese population.

Nguyen TV, Janssen MJ, van Oijen MG, Bergevoet SM, te Morsche RH, van Asten H, Laheij RJ, Peters WH, Jansent JB.

Oncol Res. 2010;18(7):349-55.

PMID:
20377137
11.

MicroRNA hsa-miR-135b regulates mineralization in osteogenic differentiation of human unrestricted somatic stem cells.

Schaap-Oziemlak AM, Raymakers RA, Bergevoet SM, Gilissen C, Jansen BJ, Adema GJ, Kögler G, le Sage C, Agami R, van der Reijden BA, Jansen JH.

Stem Cells Dev. 2010 Jun;19(6):877-85. doi: 10.1089/scd.2009.0112.

PMID:
19795981
12.

Exclusion of ABCB8 and ABCB10 as cancer candidate genes in acute myeloid leukemia.

Tang L, Bergevoet SM, Franssen LE, de Witte T, Jansen JH, Raymakers RA, van der Reijden BA.

Leukemia. 2009 May;23(5):1000-2. doi: 10.1038/leu.2008.358. Epub 2009 Jan 8. No abstract available.

PMID:
19151771
13.

Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer.

van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Yv, Wobbes T, Nagengast FM, Peters WH.

Mutat Res. 2006 Jan 29;593(1-2):39-49. Epub 2005 Jul 21.

PMID:
16039674
14.

Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk.

van der Logt EM, Bergevoet SM, Roelofs HM, van Hooijdonk Z, te Morsche RH, Wobbes T, de Kok JB, Nagengast FM, Peters WH.

Carcinogenesis. 2004 Dec;25(12):2407-15. Epub 2004 Aug 19.

PMID:
15319294

Supplemental Content

Loading ...
Support Center